| Name | Anamosa Care Center |
|---|---|
| Location | 1209 East Third Street, Anamosa, Iowa |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 64 |
| Occupancy Rate | 70.63% |
| Medicare ID (CCN) | 165375 |
| Legal Business Name | Anamosa Nursing Home Company Llc |
| Ownership Type | For Profit - Individual |
| NPI Number | 1134347826 |
| Organization Name | ANAMOSA NURSING HOME COMPANY LLC |
| Doing Business As | ANAMOSA CARE CENTER |
| Address | 1209 E 3rd St, Anamosa, IA 52205 |
| Phone Number | 319-462-4356 |
News Archive
U.S. Food and Drug Administration (FDA) researchers say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center.
That's one conclusion from a new study that looked at how virulence evolves in parasites. The research examined whether parasites evolve to be more or less aggressive depending on whether they are closely connected to their hosts or scattered among more isolated clusters of hosts.
A new study reports the results of a model framed to explore the transmission of the delta variant among schoolchildren and the most effective intervention methods to minimize such spread.
An international team of scientists — led by researchers from the University of Washington and two other institutions — has announced that a new compound to fight malaria is ready for human trials. In a new paper published July 15 in Science Translational Medicine, they show that this compound is the first to cripple a critical protein that the malaria parasite needs to survive at different stages of its complex life cycle, and is suitable for clinical tests in humans.
› Verified 2 days ago
| NPI Number | 1659330470 |
| Organization Name | ANAMOSA NURSING HOME COMPANY LLC |
| Doing Business As | ANAMOSA CARE CENTER |
| Address | 1209 E 3rd St, Anamosa, IA 52205 |
| Phone Number | 319-462-4356 |
News Archive
U.S. Food and Drug Administration (FDA) researchers say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center.
That's one conclusion from a new study that looked at how virulence evolves in parasites. The research examined whether parasites evolve to be more or less aggressive depending on whether they are closely connected to their hosts or scattered among more isolated clusters of hosts.
A new study reports the results of a model framed to explore the transmission of the delta variant among schoolchildren and the most effective intervention methods to minimize such spread.
An international team of scientists — led by researchers from the University of Washington and two other institutions — has announced that a new compound to fight malaria is ready for human trials. In a new paper published July 15 in Science Translational Medicine, they show that this compound is the first to cripple a critical protein that the malaria parasite needs to survive at different stages of its complex life cycle, and is suitable for clinical tests in humans.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
U.S. Food and Drug Administration (FDA) researchers say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center.
That's one conclusion from a new study that looked at how virulence evolves in parasites. The research examined whether parasites evolve to be more or less aggressive depending on whether they are closely connected to their hosts or scattered among more isolated clusters of hosts.
A new study reports the results of a model framed to explore the transmission of the delta variant among schoolchildren and the most effective intervention methods to minimize such spread.
An international team of scientists — led by researchers from the University of Washington and two other institutions — has announced that a new compound to fight malaria is ready for human trials. In a new paper published July 15 in Science Translational Medicine, they show that this compound is the first to cripple a critical protein that the malaria parasite needs to survive at different stages of its complex life cycle, and is suitable for clinical tests in humans.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.39 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 36.84 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.04 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.43 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 1.46 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.93 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.56 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.45 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.31 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 15.67 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 21.78 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.89 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.56 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 60.1 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.17 | 82.93 |
News Archive
U.S. Food and Drug Administration (FDA) researchers say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center.
That's one conclusion from a new study that looked at how virulence evolves in parasites. The research examined whether parasites evolve to be more or less aggressive depending on whether they are closely connected to their hosts or scattered among more isolated clusters of hosts.
A new study reports the results of a model framed to explore the transmission of the delta variant among schoolchildren and the most effective intervention methods to minimize such spread.
An international team of scientists — led by researchers from the University of Washington and two other institutions — has announced that a new compound to fight malaria is ready for human trials. In a new paper published July 15 in Science Translational Medicine, they show that this compound is the first to cripple a critical protein that the malaria parasite needs to survive at different stages of its complex life cycle, and is suitable for clinical tests in humans.
› Verified 2 days ago